Parasites could become part of the armour of military personnel and first responders to help them counter chemical and biological weapon attacks in war zones.
Charles River Analytics announced Sep. 14 it was awarded a contract by the Defense Advanced Research Projects Agency (DARPA) to lead a team of research organizations seeking to develop a novel biosystem solution to protect warfighters from chemical and biological threats. The five-year, $16M contract will focus on neutralizing threats at vulnerable internal tissue barriers (including skin, airway, and ocular barriers) using a configurable biological countermeasure.
The effort is part of DARPAs Personalized Protective Biosystem (PPB) program, which is exploring the use of new transgenic commensal organismsspecifically hookworms and schistosomesto secrete therapeutics specifically targeting chemical and biological threats, including neurotoxins (such as organophosphates) and microbial pathogens.
These organisms already live naturally in humans in areas where they are endemic. They have sophisticated secretory systems that can be manipulated to provide immunotherapies to protect our women and men on the battlefield, said Dr. Bethany Bracken, Principal Scientist at Charles River Analytics and lead of the effort. Our goal is to insert a genetic sequence that provides the managed protection that the human body needs to counter these biological threats.
The effort includes a team of subcontractors including Baylor College of Medicine; George Washington University; James Cook University; Leiden University Medical Center; University of California, Irvine; and Washington University School of Medicine in St. Louis.
Professor Alex Loukas and Dr. Paul Giacomins teams from James Cook Universitys Australian Institute of Tropical Health and Medicine will receive nearly US $2.5 million over five years to conduct research as part of the effort.
Professor Loukas, a molecular parasitologist, said the project is intended to reduce the burden of personal protective equipment worn or carried by members of the military and medical first responders in conflict zones to protect them against bioterrorism agents.
What we will be doing at JCU builds on our work with parasitic helminth infections in human volunteers, said Professor Loukas.
Capitalising on recent advances in genetic modification using CRISPR-Cas9, the team will create parasitic helminths that secrete drugs that counteract bioterrorism agents, and thereby protect the parasite-infected subject against chemical and biological agents in a safe and well tolerated manner.
Professor Loukas said as military technology and technology in general advances, these kinds of threats will become more common.
It is clearly an advantage to have an internal biological solution to counter threats when they suddenly appear.
We are thinking of parasitic helminths as internal molecular foundries, producing and delivering drugs within and throughout the body continuously, or on demand, if we so choose, said Professor Loukas.
The George Washington University has been awarded a $3.6 million contract to genetically modify commensal organisms to produce antidotes for harmful biological and chemical agents.
We are genetically modifying the organisms responsible for the neglected tropical disease, schistosomiasis, to instead serve as a platform for delivering antibodies to frontline personnel who risk exposure to biological pathogens or harmful chemicals, Paul Brindley, PhD, professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences and lead investigator on the project at GW, said. Our goal is to create an anti-threat solution that can be activated in 10 minutes or less and can be quickly adapted for new threats.
Brindley and his lab colleagues at GW have expertise inusing CRISPR/Cas9 to limit the impact of schistosomiasisand liver fluke infection. Because the agents that cause these diseases are adept at entering and circulating in the human body, they represent a potentially promising delivery vehicle for carrying antibody genes into the body as well. Brindley will use CRISPR/Cas9 to plug genetic information into the DNA of male organisms. As the organisms cycle through their life, the team aims to manipulate the experimentally gene-edited segment of genetic material, or transgene, to perform programmed tasks, such as turning on and off and releasing an anti-pathogen antibody into the body. Brindley and his research team will work in concert with military labs to test against real threats.
The first phase of the contract is 24 months. If successful, additional funding will be received to progress to phase two (also 24 months) and then phase three (12 months).
We have fascinating work ahead, which could bring tremendous protective measures first to our warfighters and eventually to the medical community overall, said Rich Wronski, Program Manager for the PPB effort and Vice President and Principal Scientist at Charles River Analytics. Our team spans four countries and 14 time zones to include the worlds foremost experts on hookworms and schistosomes.
Read more from the original source:
Protective Biosystems: Parasites to Fight Chemical and Biological Weapons - Global Biodefense
- Gene Therapy May Reverse Hurler Syndrome, a Rare and Severe Illness in Kids - HealthDay - November 21st, 2021
- Immunosuppressants linked to severe reactions in people with common genetic profile - Stanford Medical Center Report - November 21st, 2021
- A video that originated on InfoWars is filled with falsehoods about COVID-19 vaccines - PolitiFact - November 21st, 2021
- Gene signature may give an upper hand in metastatic breast cancer - Baylor College of Medicine News - November 21st, 2021
- Lung cancer management in the era of precision medicine - Express Healthcare - November 21st, 2021
- Powerful gene-based testing by integrating long-range chromatin interactions and knockoff genotypes - pnas.org - November 21st, 2021
- Stoke Therapeutics Announces Presentations from the Company's Dravet Syndrome Program at the American Epilepsy Society 2021 Annual Meeting - Business... - November 21st, 2021
- European Commission approves Roche's Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer |... - November 21st, 2021
- Maternal cannabis use is associated with suppression of immune gene networks in placenta and increased anxiety phenotypes in offspring - pnas.org - November 21st, 2021
- Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With... - November 21st, 2021
- Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled... - November 21st, 2021
- Gene Therapy and Genetic Engineering - MU School of Medicine - November 17th, 2021
- Gene editing: Great for medicine but ethical issues arise - November 17th, 2021
- Gene on, gene off: Chroma Medicine turns lights on with $125M to control gene expression with ex-Editas, Regeneron leaders - FierceBiotech - November 17th, 2021
- gene therapy | Description, Uses, Examples, & Safety ... - November 17th, 2021
- Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development - Yahoo Finance - November 17th, 2021
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 17th, 2021
- 8 medical advances you may have missed during COVID-19 - AAMC - November 17th, 2021
- PNAS Papers on Woodrat Microbiome, Maternal Cannabis Use, Gene-Based Testing - GenomeWeb - November 17th, 2021
- Single Cell Multiomic Atlas of the Human Retina: An Integrative Analysis - Genetic Engineering & Biotechnology News - November 17th, 2021
- Map of Mouse Iris Offers New Look at the Eye - Howard Hughes Medical Institute - November 17th, 2021
- Is every gene associated with cancer? - Medical News Today - November 15th, 2021
- Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy - BioPharma Dive - November 15th, 2021
- A mammoth solution - Harvard Office of Technology Development - November 15th, 2021
- Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Franon PhD as Chief... - November 15th, 2021
- Cell and Gene Therapy Catapult and Deep Science Ventures collaborate to overcome barriers in ATMPs - BioPharma-Reporter.com - November 15th, 2021
- Regenerative Medicine Market to reach US$ 25,959.5 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 15th, 2021
- Dr Pengyi Yang wins National Stem Cell Foundation Metcalf Prize - News - The University of Sydney - November 15th, 2021
- Researchers make strides identifying genetic causes of rare neurodevelopmental disorders in the Turkish and worldwide populations - Baylor College of... - November 15th, 2021
- Saving the world with synthetic biology - Scope - Scope - November 15th, 2021
- GenSight Biologics to Present New Clinical Data of LUMEVOQ and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting - Business... - November 15th, 2021
- Gene Therapy ADVM-022 Provides Mixed Efficacy, Safety in Treating DME - MD Magazine - November 15th, 2021
- Role of gene associated with Alzheimer's disease in brain's immune cells investigated by scientists - Devdiscourse - November 15th, 2021
- Attitudes among parents of persons with autism spectrum disorder towards information about genetic risk and future health | European Journal of Human... - November 15th, 2021
- Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED - PRNewswire - November 15th, 2021
- Arizona researchers have a Valley fever vaccine for dogs and that's good news for humans - KJZZ - November 15th, 2021
- Study revealed the function of mysterious structure found on neurons - Tech Explorist - November 15th, 2021
- New Research Helps Explain the Genetic Basis of Why We Look the Way We Do - UC San Diego Health - November 15th, 2021
- Gene Therapy Shows Early Promise as Angelman Syndrome Treatment | Newsroom - UNC Health and UNC School of Medicine - October 26th, 2021
- Report by Mott Center researchers named NIEHS Extramural Paper of the Month - The South End - October 26th, 2021
- Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene... - October 26th, 2021
- Delic Partners With GT Research for Genetic Analysis of Cannabis, Psychedelic Mushrooms - GenomeWeb - October 26th, 2021
- Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - WABI - October 26th, 2021
- The Genomic Revolution: Why Investors Are Paying Attention - Visual Capitalist - October 26th, 2021
- Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T in Advanced ROR1+ Hematological and Solid Tumors - WAGM - October 26th, 2021
- 5 Trends Shaping the Future of eCommerce - Visual Capitalist - October 26th, 2021
- Anatomy texts should show sex as a spectrum to include intersex people - The Conversation AU - October 26th, 2021
- Early Results of Gene Therapy for Angelman Syndrome Look Promising - AJMC.com Managed Markets Network - October 24th, 2021
- Ten Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune Disease - HealthDay News - October 24th, 2021
- Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit - Yahoo Finance - October 24th, 2021
- Generation Bio Presents Data Demonstrating First Lipid Nanoparticle to Achieve Uniform Retinal Transduction and Tolerability via Sub-Retinal Delivery... - October 24th, 2021
- ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit - WCAX - October 24th, 2021
- Lovelace Biomedical Presents a New Webinar on Rare Diseases and Gene Therapy Preclinical Research - PRNewswire - October 24th, 2021
- Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there? - FiercePharma - October 24th, 2021
- Senti Bio CEO Appointed to The Alliance for Regenerative Medicine 2022 Board of Directors - StreetInsider.com - October 24th, 2021
- ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs - MedCity News - October 24th, 2021
- From cancer to Crohn, Israel pushes precision medicine to the next level - The Jerusalem Post - October 24th, 2021
- Tulane scientists unravel 50-year-old medical mystery behind toddlers' deaths from RSV vaccine - Tulane News - October 24th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 24th, 2021
- Boehringer Acquires Rights to Potential CF Inhalation Gene Therapy - Cystic Fibrosis News Today - October 24th, 2021
- LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using... - October 24th, 2021
- Global Pharmaceutical Contract Development and Manufacturing Markets, 2021-2026 - Increasing Demand for Biological & Cell and Gene Therapies /... - October 24th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - The Highland County Press - October 24th, 2021
- Hunterian Medicine Licenses Inscriptas MAD7 Nuclease to Advance Gene Editing Research and Development - Yahoo Finance - October 17th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 17th, 2021
- 4 Biotechs to Watch Amid Rising Prominence of Gene Therapies - Yahoo Finance - October 17th, 2021
- The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics - Yahoo Finance - October 17th, 2021
- Could an Old Drug Be a New Alzheimers Treatment? - AARP - October 17th, 2021
- 5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform - October 17th, 2021
- Harvard's R&D alliance with Resilience to advance manufacture of complex medicines - Harvard Gazette - October 17th, 2021
- Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress - StreetInsider.com - October 17th, 2021
- Genetic screening test leads to discovery of a family trait - Sanford Health News - October 17th, 2021
- Filling the gaps: connecting genes to diseases through proteins - EurekAlert - October 17th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 17th, 2021
- Polygenic screening of embryos is here, but is it ethical? - The Guardian - October 17th, 2021
- Wolter Earns Young Investigator Award | Newsroom - UNC Health and UNC School of Medicine - October 17th, 2021
- Patient Care on the Precipice of Transformation at Penn Medicine's New Pavilion - pennmedicine.org - October 17th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 11th, 2021
- CRISPR is revolutionizing medicine its origin story is pretty incredible, too - Freethink - October 11th, 2021
- Longevity Foundation to Fund Geroscience Research with 860M - Labiotech.eu - October 11th, 2021